Similar Efficacy, Safety, and Immune Improvement Through 96 Weeks in Individuals With Limited HIV-1 Treatment Options Using Twice-Daily Dolutegravir- or Fostemsavir-based Regimens.

Constructing suppressive regimens for individuals with multidrug-resistant HIV-1 can be challenging. Separate analyses of 96-week outcomes from the phase 3 VIKING-3 and BRIGHTE studies demonstrate that twice-daily dolutegravir-based and fostemsavir-based regimens each provide robust viral suppression, favorable safety profiles, and CD4+ T-cell count improvement in this population. Clinical trial registration VIKING-3: ClinicalTrials.gov identification number, NCT01328041; URL, https://clinicaltrials.gov/study/NCT01328041; BRIGHTE: ClinicalTrials.gov identification number, NCT02362503; URL, https://clinicaltrials.gov/study/NCT02362503.